調査レポート | • レポートコード：QYR2104Z0031 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療 |
| Single User | ￥553,800 (USD3,900) | ▷ お問い合わせ |
| Multi User/Five User | ￥830,700 (USD5,850) | ▷ お問い合わせ |
| Enterprise License（同一法人内共有可） | ￥1,107,600 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の本調査資料では、後天性孤児造血疾患治療のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（投薬、骨髄移植、輸血、鉄療法）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・後天性孤児造血疾患治療の市場動向 ・企業の競争状況、市場シェア ・後天性孤児造血疾患治療の種類別市場規模（投薬、骨髄移植、輸血、鉄療法） ・後天性孤児造血疾患治療の用途別市場規模（病院、クリニック、その他） ・後天性孤児造血疾患治療の北米市場規模2016-2027（アメリカ、カナダ） ・後天性孤児造血疾患治療のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・後天性孤児造血疾患治療のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・後天性孤児造血疾患治療の中南米市場規模2016-2027（メキシコ、ブラジル） ・後天性孤児造血疾患治療の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Alexion Pharmaceuticals、Amgen、Celgene Corporation、Eli Lilly、Sanofi、GlaxoSmithKline、Cyclacel Pharmaceuticals、Onconova Therapeutics、Incyte Corporation、CTI BioPharma） ・結論 |
Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body’s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack of red blood cells in blood, which in turn results in a decrease in platelet numbers. This decrease in platelet number causes anemia and thrombosis.
Soliris (eculizumab) is a perfect example of a successful orphan blood disease drug. PNH is a potentially life-threatening blood disease, characterised by severe anemia caused by the destruction of red blood cells in the bloodstream. Bone marrow transplants can provide a cure, but the high risk procedure is suitable for only a few patients. Treatment methods include blood transfusions, iron therapy, and growth factors, but monoclonal antibody
Market Analysis and Insights: Global Acquired Orphan Blood Diseases Therapeutics Market
The global Acquired Orphan Blood Diseases Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Acquired Orphan Blood Diseases Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Acquired Orphan Blood Diseases Therapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Acquired Orphan Blood Diseases Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Acquired Orphan Blood Diseases Therapeutics market.
Global Acquired Orphan Blood Diseases Therapeutics Scope and Market Size
Acquired Orphan Blood Diseases Therapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Acquired Orphan Blood Diseases Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.
Segment by Type
Medication
Bone Marrow Transplant
Blood Transfusion
Iron Therapy
Segment by Application
Hospitals
Clinics
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Alexion Pharmaceuticals
Amgen
Celgene Corporation
Eli Lilly
Sanofi
GlaxoSmithKline
Cyclacel Pharmaceuticals
Onconova Therapeutics
Incyte Corporation
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Medication
1.2.3 Bone Marrow Transplant
1.2.4 Blood Transfusion
1.2.5 Iron Therapy
1.3 Market by Application
1.3.1 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Acquired Orphan Blood Diseases Therapeutics Market Perspective (2016-2027)
2.2 Acquired Orphan Blood Diseases Therapeutics Growth Trends by Regions
2.2.1 Acquired Orphan Blood Diseases Therapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Acquired Orphan Blood Diseases Therapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Acquired Orphan Blood Diseases Therapeutics Industry Dynamic
2.3.1 Acquired Orphan Blood Diseases Therapeutics Market Trends
2.3.2 Acquired Orphan Blood Diseases Therapeutics Market Drivers
2.3.3 Acquired Orphan Blood Diseases Therapeutics Market Challenges
2.3.4 Acquired Orphan Blood Diseases Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Revenue
3.1.1 Global Top Acquired Orphan Blood Diseases Therapeutics Players by Revenue (2016-2021)
3.1.2 Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Acquired Orphan Blood Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Acquired Orphan Blood Diseases Therapeutics Revenue
3.4 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio
3.4.1 Global Acquired Orphan Blood Diseases Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acquired Orphan Blood Diseases Therapeutics Revenue in 2020
3.5 Acquired Orphan Blood Diseases Therapeutics Key Players Head office and Area Served
3.6 Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service
3.7 Date of Enter into Acquired Orphan Blood Diseases Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acquired Orphan Blood Diseases Therapeutics Breakdown Data by Type
4.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Type (2016-2021)
4.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Type (2022-2027)
5 Acquired Orphan Blood Diseases Therapeutics Breakdown Data by Application
5.1 Global Acquired Orphan Blood Diseases Therapeutics Historic Market Size by Application (2016-2021)
5.2 Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Application (2022-2027)
6 North America
6.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size (2016-2027)
6.2 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type
6.2.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021)
6.2.2 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027)
6.2.3 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2027)
6.3 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application
6.3.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021)
6.3.2 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027)
6.3.3 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2027)
6.4 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country
6.4.1 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021)
6.4.2 North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada
7 Europe
7.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size (2016-2027)
7.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type
7.2.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021)
7.2.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027)
7.2.3 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2027)
7.3 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application
7.3.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021)
7.3.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027)
7.3.3 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2027)
7.4 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country
7.4.1 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021)
7.4.2 Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic
8 Asia-Pacific
8.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size (2016-2027)
8.2 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Type
8.2.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Application
8.3.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region
8.4.1 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size (2016-2027)
9.2 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Type
9.2.1 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2027)
9.3 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Application
9.3.1 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2027)
9.4 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country
9.4.1 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size (2016-2027)
10.2 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Type
10.2.1 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Application
10.3.1 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country
10.4.1 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Alexion Pharmaceuticals
11.1.1 Alexion Pharmaceuticals Company Details
11.1.2 Alexion Pharmaceuticals Business Overview
11.1.3 Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction
11.1.4 Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.1.5 Alexion Pharmaceuticals Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Acquired Orphan Blood Diseases Therapeutics Introduction
11.2.4 Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.2.5 Amgen Recent Development
11.3 Celgene Corporation
11.3.1 Celgene Corporation Company Details
11.3.2 Celgene Corporation Business Overview
11.3.3 Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Introduction
11.3.4 Celgene Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.3.5 Celgene Corporation Recent Development
11.4 Eli Lilly
11.4.1 Eli Lilly Company Details
11.4.2 Eli Lilly Business Overview
11.4.3 Eli Lilly Acquired Orphan Blood Diseases Therapeutics Introduction
11.4.4 Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.4.5 Eli Lilly Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Acquired Orphan Blood Diseases Therapeutics Introduction
11.5.4 Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 GlaxoSmithKline
11.6.1 GlaxoSmithKline Company Details
11.6.2 GlaxoSmithKline Business Overview
11.6.3 GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Introduction
11.6.4 GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.6.5 GlaxoSmithKline Recent Development
11.7 Cyclacel Pharmaceuticals
11.7.1 Cyclacel Pharmaceuticals Company Details
11.7.2 Cyclacel Pharmaceuticals Business Overview
11.7.3 Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Introduction
11.7.4 Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.7.5 Cyclacel Pharmaceuticals Recent Development
11.8 Onconova Therapeutics
11.8.1 Onconova Therapeutics Company Details
11.8.2 Onconova Therapeutics Business Overview
11.8.3 Onconova Therapeutics Acquired Orphan Blood Diseases Therapeutics Introduction
11.8.4 Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.8.5 Onconova Therapeutics Recent Development
11.9 Incyte Corporation
11.9.1 Incyte Corporation Company Details
11.9.2 Incyte Corporation Business Overview
11.9.3 Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Introduction
11.9.4 Incyte Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.9.5 Incyte Corporation Recent Development
11.10 CTI BioPharma
11.10.1 CTI BioPharma Company Details
11.10.2 CTI BioPharma Business Overview
11.10.3 CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Introduction
11.10.4 CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
11.10.5 CTI BioPharma Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Table 1. Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Medication
Table 3. Key Players of Bone Marrow Transplant
Table 4. Key Players of Blood Transfusion
Table 5. Key Players of Iron Therapy
Table 6. Global Acquired Orphan Blood Diseases Therapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2016-2021)
Table 10. Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2022-2027)
Table 12. Acquired Orphan Blood Diseases Therapeutics Market Trends
Table 13. Acquired Orphan Blood Diseases Therapeutics Market Drivers
Table 14. Acquired Orphan Blood Diseases Therapeutics Market Challenges
Table 15. Acquired Orphan Blood Diseases Therapeutics Market Restraints
Table 16. Global Acquired Orphan Blood Diseases Therapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Players (2016-2021)
Table 18. Global Top Acquired Orphan Blood Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2020)
Table 19. Ranking of Global Top Acquired Orphan Blood Diseases Therapeutics Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Acquired Orphan Blood Diseases Therapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Acquired Orphan Blood Diseases Therapeutics Product Solution and Service
Table 23. Date of Enter into Acquired Orphan Blood Diseases Therapeutics Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Type (2016-2021)
Table 27. Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Acquired Orphan Blood Diseases Therapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Application (2016-2021)
Table 31. Global Acquired Orphan Blood Diseases Therapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 63. Alexion Pharmaceuticals Company Details
Table 64. Alexion Pharmaceuticals Business Overview
Table 65. Alexion Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Product
Table 66. Alexion Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 67. Alexion Pharmaceuticals Recent Development
Table 68. Amgen Company Details
Table 69. Amgen Business Overview
Table 70. Amgen Acquired Orphan Blood Diseases Therapeutics Product
Table 71. Amgen Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 72. Amgen Recent Development
Table 73. Celgene Corporation Company Details
Table 74. Celgene Corporation Business Overview
Table 75. Celgene Corporation Acquired Orphan Blood Diseases Therapeutics Product
Table 76. Celgene Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 77. Celgene Corporation Recent Development
Table 78. Eli Lilly Company Details
Table 79. Eli Lilly Business Overview
Table 80. Eli Lilly Acquired Orphan Blood Diseases Therapeutics Product
Table 81. Eli Lilly Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 82. Eli Lilly Recent Development
Table 83. Sanofi Company Details
Table 84. Sanofi Business Overview
Table 85. Sanofi Acquired Orphan Blood Diseases Therapeutics Product
Table 86. Sanofi Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 87. Sanofi Recent Development
Table 88. GlaxoSmithKline Company Details
Table 89. GlaxoSmithKline Business Overview
Table 90. GlaxoSmithKline Acquired Orphan Blood Diseases Therapeutics Product
Table 91. GlaxoSmithKline Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 92. GlaxoSmithKline Recent Development
Table 93. Cyclacel Pharmaceuticals Company Details
Table 94. Cyclacel Pharmaceuticals Business Overview
Table 95. Cyclacel Pharmaceuticals Acquired Orphan Blood Diseases Therapeutics Product
Table 96. Cyclacel Pharmaceuticals Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 97. Cyclacel Pharmaceuticals Recent Development
Table 98. Onconova Therapeutics Company Details
Table 99. Onconova Therapeutics Business Overview
Table 100. Onconova Therapeutics Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 101. Onconova Therapeutics Recent Development
Table 102. Incyte Corporation Company Details
Table 103. Incyte Corporation Business Overview
Table 104. Incyte Corporation Acquired Orphan Blood Diseases Therapeutics Product
Table 105. Incyte Corporation Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 106. Incyte Corporation Recent Development
Table 107. CTI BioPharma Company Details
Table 108. CTI BioPharma Business Overview
Table 109. CTI BioPharma Acquired Orphan Blood Diseases Therapeutics Product
Table 110. CTI BioPharma Revenue in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021) & (US$ Million)
Table 111. CTI BioPharma Recent Development
Table 112. Research Programs/Design for This Report
Table 113. Key Data Information from Secondary Sources
Table 114. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Type: 2020 VS 2027
Figure 2. Medication Features
Figure 3. Bone Marrow Transplant Features
Figure 4. Blood Transfusion Features
Figure 5. Iron Therapy Features
Figure 6. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Acquired Orphan Blood Diseases Therapeutics Report Years Considered
Figure 11. Global Acquired Orphan Blood Diseases Therapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Acquired Orphan Blood Diseases Therapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions: 2020 VS 2027
Figure 14. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Regions (2022-2027)
Figure 15. Global Acquired Orphan Blood Diseases Therapeutics Market Share by Players in 2020
Figure 16. Global Top Acquired Orphan Blood Diseases Therapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Acquired Orphan Blood Diseases Therapeutics as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Acquired Orphan Blood Diseases Therapeutics Revenue in 2020
Figure 18. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Type (2016-2021)
Figure 19. Global Acquired Orphan Blood Diseases Therapeutics Revenue Market Share by Type (2022-2027)
Figure 20. North America Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2016-2027)
Figure 22. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2016-2027)
Figure 23. North America Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2016-2027)
Figure 24. United States Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2016-2027)
Figure 28. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2016-2027)
Figure 29. Europe Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2016-2027)
Figure 30. Germany Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Acquired Orphan Blood Diseases Therapeutics Market Share by Region (2016-2027)
Figure 40. China Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2016-2027)
Figure 48. Latin America Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2016-2027)
Figure 49. Latin America Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2016-2027)
Figure 50. Mexico Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Acquired Orphan Blood Diseases Therapeutics Market Share by Country (2016-2027)
Figure 56. Turkey Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Acquired Orphan Blood Diseases Therapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. Alexion Pharmaceuticals Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 60. Amgen Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 61. Celgene Corporation Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 62. Eli Lilly Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 63. Sanofi Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 64. GlaxoSmithKline Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 65. Cyclacel Pharmaceuticals Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 66. Onconova Therapeutics Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 67. Incyte Corporation Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 68. CTI BioPharma Revenue Growth Rate in Acquired Orphan Blood Diseases Therapeutics Business (2016-2021)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
世界の後天性孤児血液疾患市場規模・現状・予測（2021年-2027年） Acquired orphan blood disease is a type of rare blood disorder, which occurs due to the presence of insufficient amount of red blood cells in the blood. This disease is characterized by the body?s inability to produce red blood cells. Moreover, improper functioning of bone marrow also leads to lack …- 世界の希少疾患市場規模・現状・予測（2021年-2027年） An orphan disease is defined as a condition that affects fewer than 200,000 people nationwide. This includes diseases as familiar as cystic fibrosis, Lou Gehrig's disease, and Tourette's syndrome, and as unfamiliar as Hamburger disease, Job syndrome, and acromegaly, or "gigantism." Some diseases hav…
- 世界の孤児肺疾患治療市場規模・現状・予測（2021年-2027年） Orphan illnesses are those which are not generally looked into, those where particular medicines are not accessible, and those which may just be of restricted enthusiasm to researchers and specialists. Orphan lung diseases are exemplified by the purported disregarded infectious diseases, which are e…
- 世界の市中肺炎（CAP）市場規模・現状・予測（2021年-2027年） Community-acquired pneumonia (CAP) refers to pneumonia (any of several lung diseases) contracted by a person with little contact with the healthcare system. The market of CAP treatment and diagnosis in further segmented with respect to major geographies of North America, Europe, Asia-Pacific, and La…
- 世界の輸血診断市場規模・現状・予測（2021年-2027年） Intravenous transfer of blood or blood products is known as blood transfusion. Replacement of lost blood components can be done with the help of blood transfusion. Blood components like red blood cells, white blood cells, platelets, clotting factors and plasma are mostly transfused. These blood comp…